全文获取类型
收费全文 | 4612篇 |
免费 | 373篇 |
国内免费 | 255篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 34篇 |
妇产科学 | 10篇 |
基础医学 | 104篇 |
口腔科学 | 25篇 |
临床医学 | 199篇 |
内科学 | 136篇 |
皮肤病学 | 20篇 |
神经病学 | 442篇 |
特种医学 | 67篇 |
外科学 | 62篇 |
综合类 | 790篇 |
预防医学 | 111篇 |
眼科学 | 34篇 |
药学 | 2368篇 |
中国医学 | 796篇 |
肿瘤学 | 33篇 |
出版年
2024年 | 7篇 |
2023年 | 15篇 |
2022年 | 48篇 |
2021年 | 82篇 |
2020年 | 85篇 |
2019年 | 69篇 |
2018年 | 127篇 |
2017年 | 99篇 |
2016年 | 111篇 |
2015年 | 124篇 |
2014年 | 281篇 |
2013年 | 310篇 |
2012年 | 335篇 |
2011年 | 355篇 |
2010年 | 232篇 |
2009年 | 242篇 |
2008年 | 253篇 |
2007年 | 300篇 |
2006年 | 249篇 |
2005年 | 248篇 |
2004年 | 183篇 |
2003年 | 189篇 |
2002年 | 158篇 |
2001年 | 149篇 |
2000年 | 127篇 |
1999年 | 96篇 |
1998年 | 87篇 |
1997年 | 79篇 |
1996年 | 64篇 |
1995年 | 51篇 |
1994年 | 59篇 |
1993年 | 63篇 |
1992年 | 50篇 |
1991年 | 44篇 |
1990年 | 35篇 |
1989年 | 28篇 |
1988年 | 33篇 |
1987年 | 22篇 |
1986年 | 19篇 |
1985年 | 16篇 |
1984年 | 18篇 |
1983年 | 19篇 |
1982年 | 18篇 |
1981年 | 10篇 |
1980年 | 11篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1976年 | 5篇 |
1975年 | 4篇 |
排序方式: 共有5240条查询结果,搜索用时 15 毫秒
1.
目的探究卡马西平与左乙拉西坦治疗成人癫痫的效果及对认知功能、骨密度的影响。方法92例成人癫痫患者作为研究对象,随机分为左乙拉西坦组与卡马西平组,各46例。左乙拉西坦组采用左乙拉西坦治疗,卡马西平组采用卡马西平治疗。比较两组患者治疗前及治疗6个月后认知功能[语言智商(VIQ)、操作智商(PIQ)、总智商(FIQ)]评分、骨密度(腰椎、股骨大转子、股骨颈)变化情况。结果治疗6个月后,两组患者VIQ、PIQ、FIQ评分均较治疗前显著提升,且左乙拉西坦组患者VIQ评分(101.2±3.1)分、PIQ评分(108.1±2.3)分、FIQ评分(105.2±1.8)分均明显高于卡马西平组的(95.1±2.8)、(94.1±2.0)、(93.5±1.6)分,差异有统计学意义(P<0.05)。治疗6个月后,卡马西平组患者腰椎、股骨大转子、股骨颈骨密度均较治疗前显著下降,且明显低于卡马西平组,差异有统计学意义(P<0.05);左乙拉西坦组治疗6个月后腰椎、股骨大转子、股骨颈骨密度与治疗前比较差异无统计学意义(P>0.05)。结论左乙拉西坦与卡马西平治疗成人癫痫,左乙拉西坦更能明显提升患者认知功能,且对患者骨密度无影响。 相似文献
2.
《Saudi Pharmaceutical Journal》2020,28(7):844-849
Epilepsy is a common neurologic disorder, which is efficiently treated with carbamazepine and valproic acid. Moreover, Saudi Ministry of Health implemented a new E-system for Poison Control Centers called Awtar to enhance technology utilization in ensuring patients’ satisfaction and to improve treatment outcomes. Therefore, we conducted this study to assess appropriateness of indication of requests and therapeutic levels of carbamazepine and valproic acid in Tabuk area, North West Saudi Arabia. This is a retrospective observational study conducted in Poison Control & Forensic Chemistry Center, Tabuk, Saudi Arabia. Patients’ data were obtained for years 2018 and 2019. The blood levels of carbamazepine and valproic acid were measured by Therapeutic Drug Monitoring (TDM) Unit. We selected patients treated with either valproic acid or carbamazepine alone without any history of drug allergy. Data of 264 patients were extracted from Awtar E-system. Serum carbamazepine levels were within therapeutic range in 114 patients (75.50%), above-therapeutic range in 13 patients (8.61%) and sub-therapeutic levels in 24 patients (15.89%). Regarding serum valproic acid, it is within therapeutic range in 62 patients (54.87%), above-therapeutic range in 11 patients (9.73%) and sub-therapeutic levels in 40 patients (35.40%). In conclusion, this study gives information about partial appropriateness of usage of carbamazepine and low level of appropriateness of valproic acid. However, more efforts are needed to improve results of appropriateness of indication of antiepileptic drugs. 相似文献
3.
扶正固本法对青少年哮喘患者基因表达的影响 总被引:1,自引:0,他引:1
目的 研究复方中药敏康片治疗青少年哮喘的疗效和作用机理。方法 选择20例青少年哮喘患者进行治疗,另设青少年特应性皮炎患者组(20例)和青少年正常组(19例)为对照。哮喘组和皮炎组口服敏康片,疗程为6个月,观察疗效、血清总IgE及FcεRIβ、IL-4Rα基因表达改变情况。结果 哮喘组显效6例,有效12例,无效2例,总有效率90%;皮炎组显效4例,有效13例,无效3例,总有效率85%;哮喘组IgE治疗前后有显著差异(P〈0.01)。皮炎组IgE治疗前后有差异(P〈0.05);用Northern blot法检测FctRlt3、IL-4Rα基因,IL-4Rα吸光度值两组治疗前均较正常组高,哮喘组治疗后降低。FcεRIβ吸光度值两组治疗前均较正常组高,治疗后均降低。结论 复方中药可以调整青少年哮喘患者相关基因表达,改善患者过敏状态,缓解临床症状。 相似文献
4.
医药行业科技成果产业化与其他行业科技成果转化相比具有更高的风险,转化能力也是最低的,因此,对其从事前、事中、事后三方面加强风险控制具有重要的观实意义。 相似文献
5.
Exacerbation of Partial Seizures and Onset of Nonepileptic Myoclonus with Carbamazepine 总被引:4,自引:3,他引:1
A child had two to three generalized tonic-clonic (GTC) seizures per week unresponsive to phenobarbital (PB) and valproate (VPA). Interictal EEG demonstrated left occipital spikes. When carbamazepine (CBZ) therapy was started, he developed very frequent (4-6/day) complex partial seizures (CPS) characterized on ictal EEG by focal right temporal lobe discharges. The seizure exacerbation, which was associated with development of nonepileptic, multifocal myoclonus, resolved 24 h after CBZ was discontinued. The exacerbation occurred with therapeutic CBZ serum levels, but may have been related to the toxic levels of carbamazepine-10, 11-epoxide (CBZE). 相似文献
6.
John G. Larkin George G. Thompson Gordon Scobie Joan E. Drennan Martin J. Brodie 《Epilepsia》1991,32(5):729-734
Interaction with adenosine A1 receptors is a possible contributory mechanism to the anticonvulsant effects of carbamazepine (CBZ) and the dihydropyridine calcium antagonists. We measured the binding of [3H]cyclohexyladenosine to adenosine A1 receptors in mouse brain stem, cerebellum, and cortex after oral administration of nifedipine, nimodipine (NMD), and CBZ for 7 days and compared the results with binding in control mice. Equilibrium dissociation constant (Kd) and receptor numbers (Bmax) were calculated using Scatchard and saturation isotherm analyses. Mean Kds (SEM) in control brain stem, cerebellum, and cortex were 2.09 (0.31), 2.39 (0.2), and 3.12 (0.28) nM, respectively. Results of Bmax for the same areas were 188 (26), 280 (24), and 449 (54) fmol/mg protein. Nifedipine (p less than 0.005) and NMD (p less than 0.02) raised the Kd of A1 receptors only in the cerebellum, and CBZ increased cerebellar Bmax (p less than 0.05). These minor effects on A1 receptors in CF1 mice, when given in doses previously shown to have anticonvulsant properties in these animals, do not suggest that alteration in A1 receptor activity is an important mechanism for the anticonvulsant effects of these drugs. 相似文献
7.
Betlach Charles J. Arnold John D. Frost R. Wayne Leese Philip T. Gonzalez Mario A. 《Pharmaceutical research》1987,4(5):409-411
The bioavailability of a new sustained-release potassium chloride (KC1) tablet, designed for once-a-day dosing, was compared to a KC1 elixir using urinary excretion data. The study utilized 25 male volunteers dosed in a crossover design in a dietary/activity-controlled environment. The regimens consisted of a total of 80 mEq of potassium in three equally divided doses of elixir every 6 hr and a single 80-mEq dose using four 20-mEq sustained-release (SR) tablets. The mean time to maximum rate of potassium urinary excretion was 2.2 hr for the first elixir dose and 5.5 hr after the SR tablet (P < 0.01), thereby supporting the prolonged-release properties of this formulation. After correction for baseline urinary potassium excretion, the mean total 24-hr urinary potassium excretion was 42.18 mEq for the elixir and 40.41 mEq for the SR tablet. The results indicate that the absorption pattern from the SR tablet is equal to three doses of KC1 elixir dosed 6 hr apart. 相似文献
8.
M S al-Humayyd 《Biopharmaceutics & drug disposition》1990,11(5):411-417
The effect of diltiazem on the plasma level of carbamazepine (CBZ) was investigated in rabbits. The animals were given either CBZ alone or in combination with diltiazem and plasma samples were collected at different time intervals. The concentration of CBZ was detected using an HPLC method. Diltiazem significantly increased the area under the curve (AUC), the maximum plasma concentration (Cmax), and the elimination half-life (t1/2) of CBZ (p less than 0.05). These results suggest that a potentially harmful drug-drug interaction may occur if CBZ and diltiazem are administered concurrently. 相似文献
9.
左旋氨氯地平治疗轻中度高血压疗效及不良反应的临床研究 总被引:14,自引:0,他引:14
目的:为评价左旋氨氯地平降压疗效及不良反应,并与氨氯地平相比较。方法:采用随机分组平行对照方法,将120例轻、中度高血压患者分成左旋氨氯地平组(60例),口服2.5~5mg·d~(-1)和氨氯地平组(60例),口服5~10mg·d~(-1)。观察5周。每周一次上午延迟1~4小时用药并测诊室谷值坐位血压、心率、观察不良反应。结果:5周未左旋氨氯地平与氨氯地平组治疗有效反应率分别为86.7%和83.3%,每组治疗前后比较差异非常显著(P<0.01)。组间比无显著性差异(P>0.05)。左旋氨氯地平组不良反应发生率6.7%,氨氯地平组为16.7%(P>0.05),但试验组不良反应程度更轻微。结论:左旋氨氯地平与氨氯地平治疗高血压同样有效,不良反应可能更小。 相似文献
10.
目的:评价泰勒宁片和科洛曲片对隆乳手术后疼痛的疗效和不良反应。方法:采用随机开放平行对照试验。共完成60例,其中A组30例予泰勒宁片,单次1片;B组30例予科洛曲片,单次1片。结果:泰勒宁片对隆乳手术后引起的中度或重度疼痛总有效率可达96.7%,科洛曲片的总有效率可达83.3%。服药后泰勒宁片组的疼痛强度差均高于科洛曲组,经统计学处理,有显著性差异(P<0.05)。不良反应发生率较科洛曲片组高。结论:泰勒宁片为中强度镇痛药,对于隆乳手术后引起的中重度疼痛有良好的镇痛效果。 相似文献